For the clinical application of ADS024 in UC, it was shown that oral live ADS024 bacterial treatment successfully ameliorated DSS colitis in mice and with reduced weight loss, disease activity, mucosal injury, and colonic IL-6 and TNFα expression (Figures 5, 6). This evidence concerns the gene IL6 and colitis.